C

China National Medicines Corp Ltd
SSE:600511

Watchlist Manager
China National Medicines Corp Ltd
SSE:600511
Watchlist
Price: 28.88 CNY -1.06% Market Closed
Market Cap: 21.8B CNY

China National Medicines Corp Ltd's latest stock split occurred on Jun 3, 2009

The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.

The adjusted shares began trading on Jun 3, 2009. This was China National Medicines Corp Ltd's 2nd stock split, following the previous one in Jun 25, 2008.

Last Splits:
Jun 3, 2009
2-for-1
Jun 25, 2008
9-for-5
Pre-Split Price
N/A
Post-Split Price
11.5627
Before
After
Last Splits:
Jun 3, 2009
2-for-1
Jun 25, 2008
9-for-5

China National Medicines Corp Ltd
Stock Splits History

China National Medicines Corp Ltd Stock Splits Timeline
Jun 3, 2009
Jun 3, 2009
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
11.5627
Before
After
Jun 25, 2008
Jun 25, 2008
Split 9-for-5
x1.8
Pre-Split Price
N/A
Post-Split Price
11.5627
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
45.22 45.22 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
81 81 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
61.4 61.4 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
47.945 47.945 USD N/A
Load More

China National Medicines Corp Ltd
Glance View

Market Cap
21.8B CNY
Industry
Health Care

China National Medicines Corp Ltd., often known as Sinopharm Group's public face, is a leviathan in the realm of pharmaceutical distribution. Headquartered in Beijing, this company is deeply entrenched in the layers of China's healthcare system. Its operations are woven through a vast network that includes the wholesale and retail distribution of an extensive range of pharmaceutical products. The company prides itself on streamlining the supply chain, connecting pharmaceutical manufacturers directly with hospitals, clinics, and pharmacies. By leveraging its logistical expertise and expansive reach, Sinopharm ensures that essential medicines flow seamlessly from producers to end-users, maintaining the vital heartbeat of the healthcare industry across China. In addition to its core distribution business, China National Medicines Corp Ltd. delves into the realm of medical device distribution and other healthcare-related services, diversifying its revenue streams. A significant portion of its income comes from partnerships and agreements with international pharmaceutical behemoths, allowing it to import and distribute advanced medicines and technology within China. By capitalizing on these strategic alliances, the company not only bolsters its portfolio but also strengthens its market position. This symbiotic relationship with both domestic and global players underpins its financial performance, making China National Medicines not just a distributor but a pivotal gatekeeper in the evolving landscape of China's healthcare industry.

Intrinsic Value
46.08 CNY
Undervaluation 37%
Intrinsic Value
Price
C
Back to Top